ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

DEME shares surge 7% on record first-half results

Belgian marine contractor posts €2.2 billion revenue, 20% net income rise and raises 2026 outlook after strongest H1 in 150 years.

PA
Priya Anand · Equities & Earnings Desk · 26 Aug 2026 · 19:46 · 1 min read
Share
DEME shares surge 7% on record first-half results

Shares of DEME NV jumped 7.1% on Tuesday after the Belgian marine engineering group reported its strongest first-half performance in 150 years, with revenue rising 2% to €2.2 billion and net income up 20% to €215 million.

The Brussels-based company said EBITDA totaled €466 million for the six months, representing a 21.6% margin. Analysts at Kepler Cheuvreux described the figures as solid, noting EBITDA exceeded consensus while net income surpassed expectations by a notably wide margin. The brokerage also forecast upward revisions to full-year earnings estimates.

DEME raised its full-year outlook, projecting revenue to slightly exceed 2025 levels while maintaining the prior-year EBITDA margin. The Dredging and Infrastructure segment delivered a positive surprise, while the Offshore Energy division maintained robust margins.

The stock advanced to a session high of €182.80, up from an opening price of €178, as trading on Euronext Brussels turned positive. U.S. equity benchmarks, including the S&P 500 and Dow Jones, held near unchanged levels, with no major Belgian or eurozone macroeconomic releases or central bank actions influencing the session.

The company’s performance follows a broader trend of strong gains among industrial peers, including Siemens Energy, which has rallied more than 230% this year.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT